BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical...
140 insider purchases on record · latest filing 2026-08-18.
Insiders have also filed 3 sale transactions at BCDA.